PMID- 1276544
OWN - NLM
STAT- MEDLINE
DCOM- 19760901
LR  - 20190509
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 57
IP  - 1
DP  - 1976 May
TI  - The inhibition by glucagon of the vasoconstrictor actions of noradrenaline, 
      angiotensin and vasopressin on the hepatic arterial vascular bed of the dog.
PG  - 93-102
AB  - 1 The hepatic artery of the anaesthetized dog was cannulated and perfused from a 
      femoral artery, the blood flow and perfusion pressure being monitored 
      continuously. The sympathetic periarterial nerves were divided. 2 Dose-dependent 
      increases in hepatic arterial vascular resistance (HAVR) resulted from 
      intra-arterial injections of noradrenaline, angiotensin and vasopressin. 3 Single 
      injections of glucagon (100 mug, i.a.) caused a transient significant fall in 
      HAVR of 19.9 +/- 3.2%, and infusions of 25 mug/min of glucagon intra-arterially 
      caused maintained reductions in HAVR of 16.9 +/- 4.2%. 4 After single injections 
      of 100 mug glucagon intra-arterially the vasoconstrictor responses to 
      noradrenaline, angiotensin, and vasopressin were reduced by about 85-95%. 
      Recovery occurred in 8-10 minutes. 5 Intra-arterial infusions of glucagon, 
      2.5-50.0 mug/min, reduced the effects of test doses of noradrenaline, angiotensin 
      and vasopressin throughout the period of the infusions. 6 Dose-response curves to 
      the constrictor agents were constructed before, during and after intra-arterial 
      infusions of 25 mug/min of glucagon. Glucagon caused a parallel shift of the 
      curves for noradrenaline and angiotensin to the right, with no suppression of the 
      maximum response. 7 Infusions of glucagon shifted the dose-response curve for 
      vasopressin to the right, but, in contrast to noradrenaline and angiotensin, the 
      shift was nonparallel and there was a suppression of the maximum response by 
      about one-half. 8 A large dose of insulin, 10 iu, transiently reduced HAVR and 
      caused a weak and very transient inhibition of the effect of test doses of 
      noradrenaline. The characteristics of these effects were quite different from 
      those of glucagon. 9 It is possible that the antagonism by glucagon of the 
      vasoconstrictor responses of the hepatic arterial vasculature may be important in 
      protecting this vascular bed from the effects of concomitantly released 
      vasoconstrictor agents.
FAU - Richardson, P D
AU  - Richardson PD
FAU - Withrington, P G
AU  - Withrington PG
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Vasoconstrictor Agents)
RN  - 11000-17-2 (Vasopressins)
RN  - 11128-99-7 (Angiotensin II)
RN  - 9007-92-5 (Glucagon)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Angiotensin II/*antagonists & inhibitors
MH  - Animals
MH  - Blood Pressure/drug effects
MH  - Dogs
MH  - Glucagon/*pharmacology
MH  - Liver Circulation/*drug effects
MH  - Norepinephrine/*antagonists & inhibitors
MH  - Organ Size/drug effects
MH  - Vascular Resistance/drug effects
MH  - *Vasoconstrictor Agents
MH  - Vasopressins/*antagonists & inhibitors
PMC - PMC1667017
EDAT- 1976/05/01 00:00
MHDA- 1976/05/01 00:01
PMCR- 1977/05/01
CRDT- 1976/05/01 00:00
PHST- 1976/05/01 00:00 [pubmed]
PHST- 1976/05/01 00:01 [medline]
PHST- 1976/05/01 00:00 [entrez]
PHST- 1977/05/01 00:00 [pmc-release]
AID - 10.1111/j.1476-5381.1976.tb07659.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1976 May;57(1):93-102. doi: 10.1111/j.1476-5381.1976.tb07659.x.